INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >

Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >

Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World leading genome sequencing and bioinformatics capability

Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry, Multiplex IF and Cytex Animal models – Syngeneic and humanized models Immune profiling by NGS – Single Cell RNAseq, Mutation burden and TCR/BCR repertoire Clinical biomarker services – CAP certification and GCP compliance

A large collection of cell line-derived xenograft (CDX) tumor models 215 validated models, SOC data available World leading imaging based orthotopic/metastatic CDX platform 28 models covering 16 tumor types

Integrated Oncology and Immuno-oncology Platform to Enable Translational Science from Drug Discovery to Clinical Biomarker Oncology Services CRISPR/Cas9 Gene Editing In Vitro Assay and HTS Tumor models Tumor Cell Panel and Screening Immunology and Immuno-oncology Platform Clinical Biomarker Immunology Services Ligand-receptor binding assays Cellular functional assays Assays for innate immunity pathways: macrophage, MDSC, NK, DC, …Read More >

Tumors are complex ecosystems composed of different cell types with different phenotypes, status and gene profiles. Commonly used GEP tools like bulk RNA Sequencing can only display gene expression profiles as a whole, and cannot reflect the heterogeneous tumor cell change or immune composition in a tumor. Single cell RNA sequencing is a good tool …Read More >